Jose Antonio Lopez-Martin

8PUBLICATIONS
52CO-AUTHORS
Predictive and prognostic markersPharmacogenomicsMolecular targetsInfectious diseasesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 16, 2024
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial.

David S Moura, Jesus M Lopez-Marti, Iva Benesova

|Aug 25, 2024
A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19.

Pedro Landete, Olga-Adriana Caliman-Sturdza, Jose A Lopez-Martin

|Oct 21, 2022
A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors.

Javier Martin-Broto, Andres Redondo, David S Moura

|Jan 11, 2022
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.

Jose F Varona, Pedro Landete, Jose A Lopez-Martin

|Dec 02, 2021
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.

Maria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas

|Jun 02, 2021
Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.

José F Varona, Pedro Landete, Jose A Lopez-Martin

Pageof 2

Frequent Collaborators

2 joint publications

Jose-Felipe Varona

2 joint publications

Javier Martin-Broto

2 joint publications

Nadia Hindi

2 joint publications

Javier Martinez-Trufero